Tushar Manudhane
Stock Analyst at Motilal Oswal
(3.49)
# 2,283
Out of 5,020 analysts
7
Total ratings
100%
Success rate
45%
Average return
Main Sectors:
Stocks Rated by Tushar Manudhane
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NSE: CIPLA Cipla Limited | Reiterated: Hold | n/a | $1,344.00 | - | 2 | Jul 24, 2026 | |
| NSE: RUBICON Rubicon Research Limited | Reiterated: Buy | ₹955.00 → ₹1,160 | ₹1,631 | -28.87% | 2 | May 30, 2026 | |
| NSE: MANKIND Mankind Pharma Limited | Reiterated: Buy | ₹2,640 | ₹2,535 | +4.14% | 1 | Apr 29, 2026 | |
| NSE: APOLLOHOSP Apollo Hospitals Enterprise Limited | Reiterated: Buy | ₹8,050 | ₹8,134 | n/a | 1 | May 31, 2025 | |
| NSE: AUROPHARMA Aurobindo Pharma Limited | Reiterated: Buy | ₹1,370 | ₹1,677 | n/a | 1 | May 28, 2025 |
Cipla Limited
Jul 24, 2026
Reiterated: Hold
Price Target: n/a
Current: $1,344.00
Upside: -
Rubicon Research Limited
May 30, 2026
Reiterated: Buy
Price Target: ₹955.00 → ₹1,160
Current: ₹1,631
Upside: -28.87%
Mankind Pharma Limited
Apr 29, 2026
Reiterated: Buy
Price Target: ₹2,640
Current: ₹2,535
Upside: +4.14%
Apollo Hospitals Enterprise Limited
May 31, 2025
Reiterated: Buy
Price Target: ₹8,050
Current: ₹8,134
Upside: n/a
Aurobindo Pharma Limited
May 28, 2025
Reiterated: Buy
Price Target: ₹1,370
Current: ₹1,677
Upside: n/a